BioCryst Pharmaceuticals, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Quarterly earnings show how well the company is doing financially and whether it's growing.
Updates investors on recent news and financial performance for the quarter ended June 30, 2026.
The company is spending money to close a research facility, which reduces cash available for other uses.
The company is shutting down internal drug discovery to focus on rare disease treatments instead.
More employee stock options dilute existing shareholders' ownership if the company gives out the new shares.
Quarterly earnings show company progress and whether revenue and expenses are meeting expectations.
Updates investors on financial performance and company strategy for the quarter ended March 31, 2026.
Stocky reads BioCryst Pharmaceuticals, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
BioCryst Pharmaceuticals, Inc.'s most recent tracked filing was a 10-Q on 5 Aug 2026: Reports second quarter 2026 financial results.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.